New York State Common Retirement Fund boosted its position in Cytek Biosciences, Inc. (NASDAQ:CTKB – Free Report) by 66.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,379,285 shares of the company’s stock after buying an additional 552,162 shares during the quarter. New York State Common Retirement Fund owned approximately 1.02% of Cytek Biosciences worth $12,676,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Susquehanna International Group LLP grew its holdings in shares of Cytek Biosciences by 444.4% during the first quarter. Susquehanna International Group LLP now owns 307,020 shares of the company’s stock valued at $2,822,000 after purchasing an additional 250,620 shares during the last quarter. State Street Corp boosted its position in shares of Cytek Biosciences by 1.0% during the first quarter. State Street Corp now owns 2,059,272 shares of the company’s stock worth $18,925,000 after buying an additional 20,927 shares during the period. Geode Capital Management LLC boosted its position in shares of Cytek Biosciences by 4.7% during the first quarter. Geode Capital Management LLC now owns 1,869,470 shares of the company’s stock worth $17,180,000 after buying an additional 83,335 shares during the period. Deutsche Bank AG boosted its position in shares of Cytek Biosciences by 33.0% during the first quarter. Deutsche Bank AG now owns 75,094 shares of the company’s stock worth $690,000 after buying an additional 18,637 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of Cytek Biosciences by 7.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 21,534 shares of the company’s stock worth $198,000 after buying an additional 1,558 shares during the period. 56.50% of the stock is owned by institutional investors.
In other news, CEO Wenbin Jiang sold 20,000 shares of the stock in a transaction on Friday, July 7th. The stock was sold at an average price of $8.48, for a total transaction of $169,600.00. Following the completion of the sale, the chief executive officer now owns 7,633,467 shares in the company, valued at approximately $64,731,800.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders sold 126,000 shares of company stock worth $1,034,150. Insiders own 15.90% of the company’s stock.
Analyst Upgrades and Downgrades
Cytek Biosciences Price Performance
CTKB opened at $7.26 on Thursday. The company has a market capitalization of $989.97 million, a price-to-earnings ratio of -181.50 and a beta of 0.45. Cytek Biosciences, Inc. has a 1-year low of $6.45 and a 1-year high of $15.90. The business has a 50 day moving average price of $8.39 and a two-hundred day moving average price of $8.82.
Cytek Biosciences (NASDAQ:CTKB – Get Free Report) last released its earnings results on Tuesday, August 8th. The company reported ($0.02) earnings per share for the quarter. The firm had revenue of $49.69 million during the quarter, compared to analyst estimates of $46.52 million. Cytek Biosciences had a negative return on equity of 0.37% and a negative net margin of 3.31%.
Cytek Biosciences Company Profile
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis.
- Five stocks we like better than Cytek Biosciences
- How to Invest in Renewable Energy
- Is Enbridge Stock Too Cheap to Pass Up Now?
- 3 Fintech Stocks With Good 2021 Prospects
- 5 Best REIT Alternatives for Passive Real Estate Income
- Investing in the Best Airline Stocks
- 5 Reasons Kroger Should Be On Every Income Investor Watchlist
Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.